[Ip-health] Talking point on Cipro patent dispute

[Michael H. Davis]

This is a multi-part message in MIME format.
--------------854351A06AB82EE1571F6C46
Content-Type: text/plain; charset=us-ascii
Content-Transfer-Encoding: 7bit

It would be interesting to know the role of Bayer in whatever evidence supports
this, aside from the tests already cited with absurdly small sample sizes.
Patent holders routinely support tests that will allow them to have an
indication that other, non patented but equally effective drugs, do not have.
And why would anyone assume that those developing resistant strains would not
develop a strain resistant to the one drug that has the so-called
"scientifically approved indication?"

Mickey

Khalil Elouardighi wrote:

> Ciprofloxacin is the only drug with scientifically approved indication for
> resistant-strain anthrax. Survival from lung anthrax infection depends on
> extremely early therapeutic success (if you don't treat it early, and treat
> it successfully, you die). If the US wants to be ready for massive resistant
> anthrax attacks fast, then it NEEDS stockpiles of all drugs known to be
> effective against anthrax, and above all of ciprofloxacin, which is the only
> drug rationaled to be effective against otherwise resistant anthrax strains.
>
> ANTHRAX : PATENTS CHALLENGE US SECURITY
>
> Khalil Elouardighi
> ACT UP-Paris.
>
> -----------
>
> Mickey Davis wrote:
> Jamie: There is (at least?) one additional fact needed: are there equally
> effective and accessible alternatives? According to Drs. Wolf and Lurie in
> the Times today, there are at least two other drugs (penicillin and
> doxycycline) that are effective and (more) accessible substitutes. Although
> the test they cite seemed to give the edge to one of
> those--doxycycline--substitutes over the other--penicillin--the sample size
> (ten) is obviously too small to reach any significant conclusions. In fact,
> based on the sample size, there is no significant evidence to indicate that
> either--penicillin or doxycycline--might not be superior.
>
> If equally or more effective alternatives are available at lower cost, why
> should we reward the more expensive, patented, alternative with increased
> sales (whether by government edict or otherwise)?
>
> Mickey
>
> James Love wrote:
>
> > Talking point on Cipro patent dispute
> > October 24, 2001 , version 1.0
> >
> > James Love <love@cptech.org>
> > cell 1.202.361.3040
> > http://www.cptech.org/ip/health/cl/cipro/
> >
> > 1.  The need for generic ciprofloxacin depends upon three factors.
> >
> >    a.  Can terrorists deliver anthrax to large numbers of people?
> >    b.  Do the terrorists have access to strains of anthrax that are
> > resistance to other (cheaper and widely available) antibiotics?
> >    c.  Could an attack take place before Bayer could deliver large
> > quantities of cirpo?
> >
> > 2.   Based upon what we know, there is a non-zero chance that all of
> > these things could happen.  In fact, no one knows what the probability
> > is, but it clearly not a trivial risk, given the consequences.
> >
> > 3.  There is evidence that the Russians have developed strains of
> > Anthrax that are resistant to ordinary antibiotics.
> >
> > 4.  The Federation of American Scientists say that 100 kilos of Anthrax
> > could kill 1 to 3 million persons.
> > (http://www.fas.org/nuke/intro/bw/agent.htm#b02).  Many have pointed out
> > that this is difficult, but it is also not impossible. There is no
> > evidence that the terrorists can do this, but there is also no evidence
> > that they cannot do this.
> >
> > 5.  Secretary Thompson says we need medications for 10 million persons.
> > At the 120 pill recommended course of treatment for ciprofloxacin, this
> > is 1.2 billion pills.  Bayer says it can produce 2 million per day.  At
> > this rate it would take 600 days to supply 1.2 billion pills.  The US is
> > now saying it will only provide 10 doses of ciprofloxacin, and then
> > switch to a cheaper antibiotic.  The rationale for switching is not
> > clear, particular if we face an attack with a disease resistant
> > strain.
> >
> > 6.  Apparently 5 generic companies have already received US FDA
> > clearance for the quality of their ciprofloxacin, and could immediately
> > be asked to manufacture the drug.
> >
> > 7.  The US government already has the right to use patents without a
> > license, under 28 US 1498.
> > (http://www.cptech.org/ip/health/cl/us-1498.html), an authority which is
> > often used for other patents.  The US could also pass HR 1708, which
> > would address the problems in 1498 regarding compensation.
> >
> > 8.  The US can clearly address supply issues faster with six suppliers,
> > than with one. (see http://www.cptech.org/ip/health/cl/cipro/)
> >
> > 9.  The US is cutting corners on public health to protect its
> > negotiating position in the Doha WTO meeting on November 9-13, where the
> > issue of compulsory licensing of drugs, and imports under a compulsory
> > license where a country does not have domestic capacity for production,
> > is a central issue, with the US, Canada and the EU opposing the Africa
> > group.
> >
> > 10.  Americans are being put at risk in order to protect the
> > pharmaceutical companies in Africa and other developing countries.
> >
> > 11.  The entire dispute is about how much risk we are willing to
> > undertake to protect the idea that patents are more important than
> > public health.  Thompson and others are rolling the dice, hoping we
> > don't need ciprofloxacin.  I hope they are right and we don't need
> > ciprofloxacin, but I don't think we should take unncessary risks with
> > the public health, and certainly not to make a polemical point over
> > patent rights.
> >
> > --
> > James Love
> > Consumer Project on Technology
> > P.O. Box 19367, Washington, DC 20036
> > http://www.cptech.org, mailto:love@cptech.org
> > voice: 1.202.387.8030 fax 1.202.234.5176 mobile 1.202.361.3040
> > _______________________________________________
> > Ip-health mailing list
> > Ip-health@lists.essential.org
> > http://lists.essential.org/mailman/listinfo/ip-health
>
> --
> You can access my papers on the Social Science Research Network (SSRN)
> through the following url:
> http://papers.ssrn.com/sol3/cf_dev/AbsByAuth.cfm?per_id=230701
>
> --

--
You can access my papers on the Social Science Research Network (SSRN) through
the following url:
http://papers.ssrn.com/sol3/cf_dev/AbsByAuth.cfm?per_id=230701


--------------854351A06AB82EE1571F6C46
Content-Type: text/x-vcard; charset=us-ascii;
 name="michael.davis.vcf"
Content-Transfer-Encoding: 7bit
Content-Description: Card for Michael H. Davis
Content-Disposition: attachment;
 filename="michael.davis.vcf"

begin:vcard 
n:DAVIS;Prof. Michael H.
tel;fax:216-687-6881
tel;work:216-687-2228
x-mozilla-html:FALSE
org:Cleveland State University;College of Law
adr:;;1801 Euclild Avenue;Cleveland;OH;44115;US
version:2.1
email;internet:michael.davis@law.csuohio.edu
title:Professor of Law
note:Patent Attorney Admitted to Practice Before the United States Patent and Trademark Office
fn:Prof. Michael H. DAVIS
end:vcard

--------------854351A06AB82EE1571F6C46--